Isofol Medical AB Sustainability Reports
Isofol Medical AB is a clinical-stage biotechnology company focused on oncology treatments. It develops its lead drug candidate, arfolitixorin, to enhance the efficacy of standard chemotherapy for advanced colorectal cancer.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300MCXYAHG7VBHX75
FIGI: BBG00G6QJCR4
11 reports from 2016 to 2025
